Cargando…

Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters

The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rissmann, Melanie, Noack, Danny, van Riel, Debby, Schmitz, Katharina S., de Vries, Rory D., van Run, Peter, Lamers, Mart M., Geurts van Kessel, Corine H., Koopmans, Marion P. G., Fouchier, Ron A. M., Kuiken, Thijs, Haagmans, Bart L., Rockx, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295819/
https://www.ncbi.nlm.nih.gov/pubmed/35787236
http://dx.doi.org/10.1080/22221751.2022.2095932
_version_ 1784750134923362304
author Rissmann, Melanie
Noack, Danny
van Riel, Debby
Schmitz, Katharina S.
de Vries, Rory D.
van Run, Peter
Lamers, Mart M.
Geurts van Kessel, Corine H.
Koopmans, Marion P. G.
Fouchier, Ron A. M.
Kuiken, Thijs
Haagmans, Bart L.
Rockx, Barry
author_facet Rissmann, Melanie
Noack, Danny
van Riel, Debby
Schmitz, Katharina S.
de Vries, Rory D.
van Run, Peter
Lamers, Mart M.
Geurts van Kessel, Corine H.
Koopmans, Marion P. G.
Fouchier, Ron A. M.
Kuiken, Thijs
Haagmans, Bart L.
Rockx, Barry
author_sort Rissmann, Melanie
collection PubMed
description The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to reduced pathogenicity of the virus or due to pre-existing immunity from vaccination or previous infection. Here, we inoculated hamsters with Omicron BA.1 to evaluate pathogenicity and kinetics of viral shedding, compared to Delta (B.1.617.2) and to animals re-challenged with Omicron BA.1 after previous SARS-CoV-2 614G infection. Omicron BA.1 infected animals showed reduced clinical signs, pathological changes, and viral shedding, compared to Delta-infected animals, but still showed gross- and histopathological evidence of pneumonia. Pre-existing immunity reduced viral shedding and protected against pneumonia. Our data indicate that the observed decrease of disease severity is in part due to intrinsic properties of the Omicron BA.1 variant.
format Online
Article
Text
id pubmed-9295819
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-92958192022-07-20 Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters Rissmann, Melanie Noack, Danny van Riel, Debby Schmitz, Katharina S. de Vries, Rory D. van Run, Peter Lamers, Mart M. Geurts van Kessel, Corine H. Koopmans, Marion P. G. Fouchier, Ron A. M. Kuiken, Thijs Haagmans, Bart L. Rockx, Barry Emerg Microbes Infect Coronaviruses The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to reduced pathogenicity of the virus or due to pre-existing immunity from vaccination or previous infection. Here, we inoculated hamsters with Omicron BA.1 to evaluate pathogenicity and kinetics of viral shedding, compared to Delta (B.1.617.2) and to animals re-challenged with Omicron BA.1 after previous SARS-CoV-2 614G infection. Omicron BA.1 infected animals showed reduced clinical signs, pathological changes, and viral shedding, compared to Delta-infected animals, but still showed gross- and histopathological evidence of pneumonia. Pre-existing immunity reduced viral shedding and protected against pneumonia. Our data indicate that the observed decrease of disease severity is in part due to intrinsic properties of the Omicron BA.1 variant. Taylor & Francis 2022-07-17 /pmc/articles/PMC9295819/ /pubmed/35787236 http://dx.doi.org/10.1080/22221751.2022.2095932 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Coronaviruses
Rissmann, Melanie
Noack, Danny
van Riel, Debby
Schmitz, Katharina S.
de Vries, Rory D.
van Run, Peter
Lamers, Mart M.
Geurts van Kessel, Corine H.
Koopmans, Marion P. G.
Fouchier, Ron A. M.
Kuiken, Thijs
Haagmans, Bart L.
Rockx, Barry
Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
title Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
title_full Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
title_fullStr Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
title_full_unstemmed Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
title_short Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
title_sort pulmonary lesions following inoculation with the sars-cov-2 omicron ba.1 (b.1.1.529) variant in syrian golden hamsters
topic Coronaviruses
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295819/
https://www.ncbi.nlm.nih.gov/pubmed/35787236
http://dx.doi.org/10.1080/22221751.2022.2095932
work_keys_str_mv AT rissmannmelanie pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT noackdanny pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT vanrieldebby pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT schmitzkatharinas pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT devriesroryd pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT vanrunpeter pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT lamersmartm pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT geurtsvankesselcorineh pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT koopmansmarionpg pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT fouchierronam pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT kuikenthijs pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT haagmansbartl pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters
AT rockxbarry pulmonarylesionsfollowinginoculationwiththesarscov2omicronba1b11529variantinsyriangoldenhamsters